Develops antiviral therapeutics for the treatment of viral diseases including influenza and COVID-19.
Cocrystal Pharma, Inc. is a biotechnology company specializing in the discovery and advancement of antiviral therapeutics aimed at treating serious and chronic viral diseases. Leveraging cutting-edge structure-based technologies, the company focuses on developing drugs to combat infections caused by hepatitis C virus (HCV), influenza virus, coronaviruses, and norovirus.
At the forefront of its pipeline, Cocrystal Pharma, Inc. is advancing CC-31244, a non-nucleoside polymerase inhibitor designed for the treatment of HCV. This compound has successfully completed Phase IIa clinical trials. Additionally, the company is actively developing CC-42344, a PB2 inhibitor targeting influenza infections, currently in preclinical development stages. Cocrystal Pharma is also engaged in the discovery of non-nucleoside polymerase inhibitors to combat norovirus infections.
Founded on strategic collaborations, Cocrystal Pharma, Inc. has established key partnerships to enhance its antiviral drug development efforts. These include a significant collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. Additionally, the company has forged alliances with the Kansas State University Research Foundation, HitGen, and InterX Inc. to further its research capabilities and expand its antiviral compound portfolio. Headquartered in Bothell, Washington, Cocrystal Pharma is committed to pioneering advancements in antiviral therapies to address global health challenges.